(CR) Crane - Overview
Stock: Aerospace Components, Braking Systems, Sensors, Pumps, Valves
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.52% |
| Yield on Cost 5y | 1.66% |
| Yield CAGR 5y | 30.53% |
| Payout Consistency | 100.0% |
| Payout Ratio | 15.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.1% |
| Relative Tail Risk | -9.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | -3.53 |
| Character TTM | |
|---|---|
| Beta | 1.152 |
| Beta Downside | 1.102 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.02% |
| CAGR/Max DD | 1.54 |
Description: CR Crane January 06, 2026
Crane Co. (NYSE: CR) is a diversified industrial manufacturer headquartered in Stamford, Connecticut, with operations spanning the United States, Canada, the United Kingdom, Continental Europe, and other international markets. The firm reports under two primary segments: Aerospace & Electronics, which supplies OEM and aftermarket components for commercial and military aerospace, defense, and space programs; and Process Flow Technologies, which delivers a broad portfolio of fluid-handling products such as lined pipe, pumps, valves, and instrumentation.
Key recent metrics (FY 2024): revenue of $4.3 billion, up 3.2 % YoY, driven largely by a 7 % increase in aerospace aftermarket sales; operating margin of 9.5 % (vs. 8.8 % in FY 2023); and free cash flow of $420 million, supporting a dividend yield of roughly 2.0 %. The aerospace segment remains sensitive to commercial jet delivery rates and defense spending cycles, while the Process Flow segment benefits from sustained capital-expenditure trends in chemical processing, water treatment, and renewable-energy infrastructure.
Investors should watch macro-drivers such as the FAA-approved jet fleet growth forecast (≈ 2 % annual deliveries through 2028) and the U.S. defense budget outlook (projected FY 2025 increase of 2.5 % YoY), both of which underpin demand for Crane’s high-mix, high-margin components. Additionally, inflation-linked input-cost pressures and supply-chain bottlenecks in specialty alloys could compress margins if not managed. For a deeper quantitative view, see the ValueRay dashboard on CR’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 366.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.02 > 1.0 |
| NWC/Revenue: 91.38% < 20% (prev 39.44%; Δ 51.94% < -1%) |
| CFO/TA 0.10 > 3% & CFO 398.6m > Net Income 366.6m |
| Net Debt (-581.6m) to EBITDA (488.1m): -1.19 < 3 |
| Current Ratio: 5.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.6m) vs 12m ago 1.38% < -2% |
| Gross Margin: 42.20% > 18% (prev 0.40%; Δ 4180 % > 0.5%) |
| Asset Turnover: 70.97% > 50% (prev 82.52%; Δ -11.55% > 0%) |
| Interest Coverage Ratio: 38.75 > 6 (EBITDA TTM 488.1m / Interest Expense TTM 11.3m) |
Altman Z'' 6.94
| A: 0.55 (Total Current Assets 2.57b - Total Current Liabilities 465.2m) / Total Assets 3.85b |
| B: 0.38 (Retained Earnings 1.46b / Total Assets 3.85b) |
| C: 0.13 (EBIT TTM 437.9m / Avg Total Assets 3.25b) |
| D: 1.15 (Book Value of Equity 2.06b / Total Liabilities 1.79b) |
| Altman-Z'' Score: 6.94 = AAA |
Beneish M -3.32
| DSRI: 0.83 (Receivables 358.7m/407.6m, Revenue 2.31b/2.18b) |
| GMI: 0.96 (GM 42.20% / 40.31%) |
| AQI: 0.76 (AQ_t 0.26 / AQ_t-1 0.34) |
| SGI: 1.06 (Revenue 2.31b / 2.18b) |
| TATA: -0.01 (NI 366.6m - CFO 398.6m) / TA 3.85b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of CR shares?
Over the past week, the price has changed by +7.44%, over one month by -0.04%, over three months by +3.95% and over the past year by +14.15%.
Is CR a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 218.8 | 11.5% |
| Analysts Target Price | 218.8 | 11.5% |
| ValueRay Target Price | 238.6 | 21.6% |
CR Fundamental Data Overview February 07, 2026
P/E Forward = 27.7008
P/S = 4.6922
P/B = 5.2416
P/EG = 2.3881
Revenue TTM = 2.31b USD
EBIT TTM = 437.9m USD
EBITDA TTM = 488.1m USD
Long Term Debt = 1.15b USD (from longTermDebt, last quarter)
Short Term Debt = 13.5m USD (from shortTermDebt, two quarters ago)
Debt = 1.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -581.6m USD (from netDebt column, last quarter)
Enterprise Value = 11.46b USD (10.82b + Debt 1.15b - CCE 506.5m)
Interest Coverage Ratio = 38.75 (Ebit TTM 437.9m / Interest Expense TTM 11.3m)
EV/FCF = 33.20x (Enterprise Value 11.46b / FCF TTM 345.1m)
FCF Yield = 3.01% (FCF TTM 345.1m / Enterprise Value 11.46b)
FCF Margin = 14.97% (FCF TTM 345.1m / Revenue TTM 2.31b)
Net Margin = 15.90% (Net Income TTM 366.6m / Revenue TTM 2.31b)
Gross Margin = 42.20% ((Revenue TTM 2.31b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 42.65%)
Tobins Q-Ratio = 2.97 (Enterprise Value 11.46b / Total Assets 3.85b)
Interest Expense / Debt = 0.13% (Interest Expense 1.50m / Debt 1.15b)
Taxrate = 25.05% (27.3m / 109.0m)
NOPAT = 328.2m (EBIT 437.9m * (1 - 25.05%))
Current Ratio = 5.53 (Total Current Assets 2.57b / Total Current Liabilities 465.2m)
Debt / Equity = 0.56 (Debt 1.15b / totalStockholderEquity, last quarter 2.06b)
Debt / EBITDA = -1.19 (Net Debt -581.6m / EBITDA 488.1m)
Debt / FCF = -1.69 (Net Debt -581.6m / FCF TTM 345.1m)
Total Stockholder Equity = 1.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.29% (Net Income 366.6m / Total Assets 3.85b)
RoE = 19.11% (Net Income TTM 366.6m / Total Stockholder Equity 1.92b)
RoCE = 14.28% (EBIT 437.9m / Capital Employed (Equity 1.92b + L.T.Debt 1.15b))
RoIC = 16.68% (NOPAT 328.2m / Invested Capital 1.97b)
WACC = 9.19% (E(10.82b)/V(11.96b) * Re(10.16%) + D(1.15b)/V(11.96b) * Rd(0.13%) * (1-Tc(0.25)))
Discount Rate = 10.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.86%
[DCF Debug] Terminal Value 65.00% ; FCFF base≈301.5m ; Y1≈197.9m ; Y5≈90.3m
Fair Price DCF = 35.50 (EV 1.46b - Net Debt -581.6m = Equity 2.04b / Shares 57.6m; r=9.19% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -26.03 | EPS CAGR: -4.38% | SUE: 0.0 | # QB: 0
Revenue Correlation: 32.95 | Revenue CAGR: 2.03% | SUE: 0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.44 | Chg30d=-0.026 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-12-31): EPS=6.68 | Chg30d=+0.071 | Revisions Net=+3 | Growth EPS=+10.4% | Growth Revenue=+24.4%
EPS next Year (2027-12-31): EPS=7.55 | Chg30d=+0.148 | Revisions Net=+3 | Growth EPS=+13.1% | Growth Revenue=+5.8%